OYSTER POINT PHARMA, INC. AND ___________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • November 5th, 2020 • Oyster Point Pharma, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OYSTER POINT PHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation][national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
OYSTER POINT PHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • November 5th, 2020 • Oyster Point Pharma, Inc. • Biological products, (no disgnostic substances) • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between OYSTER POINT PHARMA, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
OYSTER POINT PHARMA, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 5th, 2020 • Oyster Point Pharma, Inc. • Biological products, (no disgnostic substances) • New York
Oyster Point Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
